Aytu Biopharma (AYTU) FCF Margin (2013 - 2026)

Aytu Biopharma (AYTU) has 14 years of FCF Margin data on file, last reported at 33.7% in Q1 2026.

• On a quarterly basis, FCF Margin rose 166.0% year-over-year to 33.7% in Q1 2026; TTM through Mar 2026 was 2.9%, a 1212.0% increase from a year earlier, with the FY2025 full-year figure at 3.26%, down 63.0% from the prior year.
• FCF Margin for Q1 2026 stood at 33.7%, down from 24.12% in the prior quarter.
• Over the last five years, FCF Margin for AYTU reached as high as 30.49% in Q2 2023 and fell as low as 37.67% in Q1 2022.
• Historically, FCF Margin has averaged 7.1% across 5 years, with a median of 7.65% in 2024.
• Across the five-year window, FCF Margin plunged 5463 bps in 2022 and soared 5634 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 9.47% in 2022, then soared by 92 bps to 0.72% in 2023, then surged by 2582 bps to 17.87% in 2024, then soared by 35 bps to 24.12% in 2025, then tumbled by 240 bps to 33.7% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 33.7% in Q1 2026, 24.12% in Q4 2025, and 4.45% in Q3 2025.